 Genprex Inc NASDAQ:GNPX said Tuesday that preclinical data for its lead drug candidate REQORSA, its proprietary TUSC2 immunogene therapy, in non-small cell lung cancer NSLC, will be featured in two presentations at the six-day virtual annual meeting of the American Association for Cancer Research AACR 21, starting on April 9. The preclinical data relates to the gene therapy companys TUSC2 immunogene therapy REQORSA with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to AstraZenecas Tagrisso osimertinib, for the treatment of the NSCLC group of lung cancers. 